IDEXX Laboratories (IDXX) Stock Price, News & Analysis

Company Overview

IDEXX Laboratories, Inc. (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software. Its products are used by animal hospitals and veterinary professionals to support clinical decision-making and ongoing patient care.

The company also provides diagnostic and testing solutions for livestock, poultry, and dairy producers, as well as microbiology testing products for municipal, commercial, and residential water markets. Founded in 1983, IDEXX is headquartered in Westbrook, Maine, and serves customers internationally. Jay Mazelsky has served as the company’s president and chief executive officer since 2022.

Key Stats

• Today's Range: $552.62 to $566.55
• 50-Day Range: $504.70 to $595.76
• 52-Week Range: $500.61 to $769.98
• Volume: 708,811 shs
• Average Volume: 531,547 shs
• Market Capitalization: $44.15 billion
• P/E Ratio: 39.41
• Dividend Yield: N/A
• Price Target: $744.09
• Consensus Rating: Moderate Buy

IDEXX Laboratories Stock Analysis - MarketRank™

IDEXX Laboratories scored higher than 93% of companies evaluated by MarketBeat, and ranked 31st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

IDEXX Laboratories has a consensus price target of $744.09, representing about 32.8% upside from its current price of $560.36.

Amount of Analyst Coverage

IDEXX Laboratories has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.15%

Earnings Growth

Earnings for IDEXX Laboratories are expected to grow by 12.15% in the coming year, from $14.81 to $16.61 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEXX Laboratories is 39.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.32.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEXX Laboratories is 39.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.22.

Price to Earnings Growth Ratio

IDEXX Laboratories has a PEG Ratio of 2.99. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IDEXX Laboratories has a P/B Ratio of 27.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.48% of the float of IDEXX Laboratories has been sold short.

Short Interest Ratio / Days to Cover

IDEXX Laboratories has a short interest ratio ("days to cover") of 3.91, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IDEXX Laboratories has recently increased by 1.23%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEXX Laboratories does not currently pay a dividend.

Dividend Growth

IDEXX Laboratories does not have a long track record of dividend growth.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 1.09

News Sentiment

IDEXX Laboratories has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.

Search Interest

4 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,172,172.00 in company stock.

Percentage Held by Insiders

0.79% of the stock of IDEXX Laboratories is held by insiders.

Percentage Held by Institutions

87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/18/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:IDXX
• CIK: 874716
• Web: www.idexx.com
• Phone: (207) 556-0300
• Fax: 207-556-4346
• Employees: 11,000
• Year Founded: 1983

Price Target and Rating

• Average Price Target for IDEXX Laboratories: $744.09
• High Price Target: $830.00
• Low Price Target: $670.00
• Potential Upside/Downside: +32.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $14.22
• Trailing P/E Ratio: 39.41
• Forward P/E Ratio: 37.84
• P/E Growth: 2.99
• Net Income: $1.06 billion
• Net Margins: 25.03%
• Pretax Margin: 31.28%
• Return on Equity: 71.96%
• Return on Assets: 33.60%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 1.17
• Quick Ratio: 0.87

Sales & Book Value

• Annual Sales: $4.30 billion
• Price / Sales: 10.26
• Cash Flow: $15.09 per share
• Price / Cash Flow: 37.14
• Book Value: $20.10 per share
• Price / Book: 27.88

Miscellaneous

• Outstanding Shares: 78,780,000
• Free Float: 78,159,000
• Market Cap: $44.15 billion
• Optionable: Optionable
• Beta: 1.55